Novo Nordisk in €1bn deal for RNA-based heart disease therapies


Novo Nordisk has struck a €1bn deal for a German biotech developing ribonucleic acid-based therapies to treat heart disease, as the Danish group invests the windfall from its best-selling diabetes and weight loss drugs. 

The acquisition of Cardior Pharmaceuticals will give Novo Nordisk a treatment for heart failure in mid-stage trials that targets the root causes of heart disease.

Novo Nordisk, the maker of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, said the transaction was an “important step” in its strategy to “establish a presence in cardiovascular disease”.